Pneumococcal Choline-Binding Proteins Involved in Virulence As Vaccine Candidates

Overview

Journal Vaccines (Basel)

Date 2021 Mar 6

PMID 33672701

Citations 10

Authors

Julio Sempere

Mirella Llamosi

Idoia Del Rio Menendez

Beatriz Lopez Ruiz

Mirian Domenech

Fernando Gonzalez-Camacho

Affiliations

Soon will be listed here.

Abstract

is a pathogen responsible for millions of deaths worldwide. Currently, the available vaccines for the prevention of infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV-23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes (up to 100 different serotypes have been identified) and are unable to protect against non-vaccine serotypes and non-encapsulated pneumococci. The emergence of antibiotic-resistant non-vaccine serotypes after these vaccines is an increasing threat. Therefore, there is an urgent need to develop new pneumococcal vaccines which could cover a wide range of serotypes. One of the vaccines most characterized as a prophylactic alternative to current PPV-23 or PCVs is a vaccine based on pneumococcal protein antigens. The choline-binding proteins (CBP) are found in all pneumococcal strains, giving them the characteristic to be potential vaccine candidates as they may protect against different serotypes. In this review, we have focused the attention on different CBPs as vaccine candidates because they are involved in the pathogenesis process, confirming their immunogenicity and protection against pneumococcal infection. The review summarizes the major contribution of these proteins to virulence and reinforces the fact that antibodies elicited against many of them may block or interfere with their role in the infection process.

Citing Articles

PCV13 vaccine prevents pneumococcal biofilms without affecting population within the polymicrobial biofilm.

Sempere J, Yuste J, Domenech M Front Immunol. 2024; 15:1495932.

PMID: 39555077 PMC: 11563816. DOI: 10.3389/fimmu.2024.1495932.

Biological puzzles solved by using : a historical review of the pneumococcal studies that have impacted medicine and shaped molecular bacteriology.

Hiller N, Orihuela C J Bacteriol. 2024; 206(6):e0005924.

PMID: 38809015 PMC: 11332154. DOI: 10.1128/jb.00059-24.

Recent progress in pneumococcal protein vaccines.

Li S, Liang H, Zhao S, Yang X, Guo Z Front Immunol. 2023; 14:1278346.

PMID: 37818378 PMC: 10560988. DOI: 10.3389/fimmu.2023.1278346.

Emerging vaccine strategies against the incessant pneumococcal disease.

Duke J, Avci F NPJ Vaccines. 2023; 8(1):122.

PMID: 37591986 PMC: 10435554. DOI: 10.1038/s41541-023-00715-w.

Immunoinformatics-aided design of a new multi-epitope vaccine adjuvanted with domain 4 of pneumolysin against Streptococcus pneumoniae strains.

Shafaghi M, Bahadori Z, Madanchi H, Ranjbar M, Shabani A, Mousavi S BMC Bioinformatics. 2023; 24(1):67.

PMID: 36829109 PMC: 9951839. DOI: 10.1186/s12859-023-05175-6.

References

Zhang F, Lu Y, Malley R . Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci U S A. 2013; 110(33):13564-9. PMC: 3746895. DOI: 10.1073/pnas.1307228110. View

Moscoso M, Obregon V, Lopez R, Garcia J, Garcia E . Allelic variation of polymorphic locus lytB, encoding a choline-binding protein, from streptococci of the mitis group. Appl Environ Microbiol. 2005; 71(12):8706-13. PMC: 1317417. DOI: 10.1128/AEM.71.12.8706-8713.2005. View

Seiberling M, Bologa M, Brookes R, Ochs M, Go K, Neveu D . Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. 2012; 30(52):7455-60. DOI: 10.1016/j.vaccine.2012.10.080. View

Lee G, Huang S, Rifas-Shiman S, Hinrichsen V, Pelton S, Kleinman K . Epidemiology and risk factors for Staphylococcus aureus colonization in children in the post-PCV7 era. BMC Infect Dis. 2009; 9:110. PMC: 2716346. DOI: 10.1186/1471-2334-9-110. View

Llull D, Lopez R, Garcia E . Characteristic signatures of the lytA gene provide a basis for rapid and reliable diagnosis of Streptococcus pneumoniae infections. J Clin Microbiol. 2006; 44(4):1250-6. PMC: 1448622. DOI: 10.1128/JCM.44.4.1250-1256.2006. View

Xu Q, Zhang J, Chen Y, Li Q, Jiang Y . Crystal structure of the choline-binding protein CbpJ from Streptococcus pneumoniae. Biochem Biophys Res Commun. 2019; 514(4):1192-1197. DOI: 10.1016/j.bbrc.2019.05.053. View

Kim J, Romero-Steiner S, Sorensen U, Blom J, Carvalho M, Barnard S . Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun. 1999; 67(5):2327-33. PMC: 115974. DOI: 10.1128/IAI.67.5.2327-2333.1999. View

Hammerschmidt S, Agarwal V, Kunert A, Haelbich S, Skerka C, Zipfel P . The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol. 2007; 178(9):5848-58. DOI: 10.4049/jimmunol.178.9.5848. View

Hollingshead S, Becker R, Briles D . Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun. 2000; 68(10):5889-900. PMC: 101551. DOI: 10.1128/IAI.68.10.5889-5900.2000. View

10.

Xu Q, Pryharski K, E Pichichero M . Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model. Vaccine. 2016; 35(2):337-344. DOI: 10.1016/j.vaccine.2016.11.046. View

11.

Perez-Dorado I, Galan-Bartual S, Hermoso J . Pneumococcal surface proteins: when the whole is greater than the sum of its parts. Mol Oral Microbiol. 2012; 27(4):221-45. DOI: 10.1111/j.2041-1014.2012.00655.x. View

12.

Keller L, Jones C, Thornton J, Sanders M, Swiatlo E, Nahm M . PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun. 2012; 81(1):173-81. PMC: 3536125. DOI: 10.1128/IAI.00755-12. View

13.

Henriques-Normark B, Tuomanen E . The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013; 3(7). PMC: 3685878. DOI: 10.1101/cshperspect.a010215. View

14.

Briles D, Ades E, Paton J, Sampson J, Carlone G, Huebner R . Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun. 2000; 68(2):796-800. PMC: 97207. DOI: 10.1128/IAI.68.2.796-800.2000. View

15.

Sakai F, Talekar S, Lanata C, Grijalva C, Klugman K, Vidal J . Expression of Streptococcus pneumoniae Virulence-Related Genes in the Nasopharynx of Healthy Children. PLoS One. 2013; 8(6):e67147. PMC: 3688971. DOI: 10.1371/journal.pone.0067147. View

16.

Xu Q, Surendran N, Verhoeven D, Klapa J, Ochs M, E Pichichero M . Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis. Vaccine. 2015; 33(8):993-1000. DOI: 10.1016/j.vaccine.2015.01.014. View

17.

Sanchez-Tatay D, Arroyo L, Tarrago D, Lirola M, Porras A, Fenoll A . Antibiotic susceptibility and molecular epidemiology of nasopharyngeal pneumococci from Spanish children. Clin Microbiol Infect. 2008; 14(8):797-801. DOI: 10.1111/j.1469-0691.2008.02025.x. View

18.

Geno K, Gilbert G, Song J, Skovsted I, Klugman K, Jones C . Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015; 28(3):871-99. PMC: 4475641. DOI: 10.1128/CMR.00024-15. View

19.

Hernani M, Ferreira P, Ferreira D, Miyaji E, Ho P, Oliveira M . Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunol Med Microbiol. 2011; 62(3):263-72. DOI: 10.1111/j.1574-695X.2011.00809.x. View

20.

Ren B, Li J, Genschmer K, Hollingshead S, Briles D . The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol. 2012; 19(10):1574-82. PMC: 3485889. DOI: 10.1128/CVI.00393-12. View